BioSpace News Archive

Arcutis Biotherapeutics, Inc. today announced positive topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, in adults and children six years and older with mild to moderate atopic dermatitis (AD).

Daré Bioscience, Inc. today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $584,986 to support activities related to development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.

PaxMedica, Inc. today provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022.

AUM Biosciences Pte. Ltd. today announced it has received Human Research Ethics Committee (“HREC”) approval to commence a Phase II clinical trial of its selective translation inhibitor AUM001 in Australia.

Travere Therapeutics, Inc. and NephCure Kidney International today announced the launch of RKD & Me, a new public awareness campaign that spotlights the real stories of people living with rare kidney disease to amplify their unique lived experiences.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. to discuss the positive initial efficacy data of the Company’s phase I/IIaa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer.

Grace Breeding Ltd. announced a strategic research and development collaboration with the University of Londrina, based in Paraná State, Brazil.

Alcon today announced the Canadian launch of its latest innovation to treat patients with dry eye: the Systane MD iLux 2MD Meibomian Gland Dysfunction (MGD) Thermal Pulsation System.

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. Today, Vyant Bio announces results for the third quarter of 2022.

Rockfield Medical Devices Limited, a commercial-stage medical device company focused on developing solutions to transform the mobility and quality of life of tube feeders, today announced U.S. Food and Drug Administration (“FDA”) 510(k) clearance of the Mobility+ Enteral Feeding System.